中国临床药理学与治疗学2023，Vol.28Issue(12)：1422-1428,7.DOI:10.12092/j.issn.1009-2501.2023.12.013
抗血小板治疗新靶点治疗急性冠脉综合征的研究进展
Research progress on new antiplatelet therapeutic targets for the treatment of acute coronary syndrome
摘要
Abstract
Acute coronary syndrome(ACS)is a cardiac acute ischemic syndrome caused by the rupture or erosion of unstable atherosclerotic plaques within the coronary artery,leading to thrombus formation.Antiplatelet therapy is a key strategy in treating ACS,and although some suc-cess has been achieved,there are still limitations,such as thrombus recurrence and bleeding side ef-fects,which limit the long-term use of drugs.Fu-ture antiplatelet therapies may achieve more effec-tive or safer treatment methods by targeting novel targets involved in platelet function.This article fo-cuses on potential target inhibitors,including GPVI,protease-activated receptor(PAR)-4,GPIb,5-hy-droxytryptamine receptor subtype 2A(5-HT2A),protein disulfide isomerase,P-selectin,and phos-phatidylinositol 3-kinase β inhibitors.关键词
急性冠脉综合征/抗血小板治疗/出血/药物Key words
acute coronary syndrome/antiplate-let therapy/bleeding/medication分类
医药卫生引用本文复制引用
刘强,任艳琴..抗血小板治疗新靶点治疗急性冠脉综合征的研究进展[J].中国临床药理学与治疗学,2023,28(12):1422-1428,7.基金项目
山西省卫生健康委科研课题(2023017) （2023017）
